2 weeks Ago By ABMN Staff
Wells Fargo & Company MN raised its holdings in shares of Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN – Free Report ) by 14.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
The fund owned 63,237 shares of the specialty pharmaceutical company’s stock after purchasing an additional 7,961 shares during the period. Wells Fargo & Company MN’s holdings in Supernus Pharmaceuticals were worth $2,287,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also bought and sold shares of the company.
Smartleaf Asset Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares in the last quarter.
Mark Sheptoff Financial Planning LLC purchased a new position in Supernus Pharmaceuticals during the 4th quarter valued at $52,000. Headlands Technologies LLC raised its holdings in Supernus Pharmaceuticals by 203.0% in the 4th quarter.
Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 1,015 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth about $72,000.
Finally, Venturi Wealth Management LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth about $92,000. Wall Street Analyst Weigh In A number of research firms recently issued reports on SUPN. Cantor Fitzgerald reissued a “neutral” rating and issued a $36.
00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 17th.
Insider Buying and Selling at Supernus Pharmaceuticals In related news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.
05. Following the sale, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95.
This represents a 10.56 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink .
Also, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.
70, for a total value of $376,236.90. Following the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at $402,915.
30. The trade was a 48.29 % decrease in their position.
The disclosure for this sale can be found here . Over the last quarter, insiders sold 11,104 shares of company stock valued at $440,263. Corporate insiders own 9.
30% of the company’s stock. Supernus Pharmaceuticals Price Performance Shares of NASDAQ SUPN opened at $32.22 on Friday.
Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.
28. The firm has a 50-day moving average of $31.94 and a 200 day moving average of $34.
97. The stock has a market cap of $1.80 billion, a P/E ratio of 30.
11 and a beta of 0.90. About Supernus Pharmaceuticals ( Free Report ) Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. Featured Articles Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc.
( NASDAQ:SUPN – Free Report ). Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
